相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice
Ling Zhao et al.
BLOOD (2012)
e-Blood High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations
Michael W. M. Kuehn et al.
BLOOD (2012)
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
Sabine Kayser et al.
BLOOD (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML
Jessica A. Pollard et al.
BLOOD (2010)
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade et al.
BLOOD (2010)
AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions
C. Haferlach et al.
LEUKEMIA (2010)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Prognostic relevance of FLT3-TKD mutations in AML:: the combination matters -: an analysis of 3082 patients
Ulrike Bacher et al.
BLOOD (2008)
Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples
L-Y Shih et al.
LEUKEMIA (2008)
FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia
Hyung-Gyoon Kim et al.
BLOOD (2008)
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
Adam J. Mead et al.
BLOOD (2007)
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years:: Results from AMLSG trial AML HD98-B
Stefan Froehling et al.
BLOOD (2006)
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21):: A Cancer and Leukemia Group B study
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
N. Boissel et al.
LEUKEMIA (2006)
Implications of NRAS mutations in AML:: a study of 2502 patients
Ulrike Bacher et al.
BLOOD (2006)
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years
DT Bowen et al.
BLOOD (2005)
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia
BF Goemans et al.
LEUKEMIA (2005)
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16):: A cancer and leukemia group B study
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Activation mutations of human c-KIT resistant to imatinib, mesylate are sensitive to the tyrosine kinase inhibitor PKC412
JD Growney et al.
BLOOD (2005)
KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor
TM Kohl et al.
BLOOD (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia:: A survey of the German Acute Myeloid Leukemia Intergroup
RF Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Risk-adapted induction and consolidation therapy in adults with de novo AML aged ≤60 years:: results of a prospective multicenter trial
G Heil et al.
ANNALS OF HEMATOLOGY (2004)
Risk-adapted postremission therapy in acute myeloid leukemia:: results of the German multicenter AML HD93 treatment trial
RF Schlenk et al.
LEUKEMIA (2003)
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML):: a survey of 110 cases from the French AML Intergroup
J Delaunay et al.
BLOOD (2003)
Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias
RS Care et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461)
JC Byrd et al.
BLOOD (2002)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)
Core-binding factors in haematopoiesis and leukaemia
NA Speck et al.
NATURE REVIEWS CANCER (2002)
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
S Schnittger et al.
BLOOD (2002)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)